Mehmet Sühha BOSTANCI, Hatice PAŞAOĞLU, Merih BAYRAM, Şehri ELBEG, Faika Ceylan SEVİNÇ

The relationship between biochemical parameters, interleukin-6 and ovarian morphology in polycystic ovary syndrome

Amaç: Bu çalışmanın amacı polikistik over sendromunda (PKOS) biyokimyasal parametreler ve interleukin-6 ile over morfolojisi ilişkisini değerlendirmektir. Gereç ve yöntem: PKOS tanısı almış 85 hasta overlerin ultrasonografik değerlendirmesine göre; grup 1 ( polikistik görünümü olmayan, n = 22), grup 2 (bir overde polikistik görüntüsü olan, n = 41) ve grup 3 (her iki overde polikistik görüntüsü olan, n = 22) olmak üzere üç gruba ayrıldı. Hastaların serum interlökin 6 (IL-6), hormone düzeyleri ve homeostasis model assessment-insulin rezistans (HOMA- IR) değerleri ölçüldü. Bulgular: Serum IL-6 seviyeleri değerlendirildiğinde, ortalama değerler gruplar için sırasıyla 14.65±6.18 pg/mL, 16.22±6.55 pg/mL ve 14.53±7.32 pg/mL olarak bulundu. Serum IL-6 düzeyleri için üç grup arasında istatistiksel olarak anlamlı bir fark yoktu (p> 0.05). Metabolik profiling değerlendirmesinde ise HOMA-IR değeri grup 2 de 3,09±1,56 bulundu ve diğer gruplara göre anlamlı düzeyde düşüktü (p

Polikistik over sendromunda biyokimyasal parametreler, interlökin-6 ve over morfolojisi arasındaki ilişki

Objectives: The aim of this study is to investigate relationships between biochemical parameters and interleukin- 6 according to the ovarian morphology in polycystic ovary syndrome (PCOS). Materials and methods: Total of 85 patients with PCOS were divided into three groups according to the ultrasonographic examination of the ovaries; group 1 (with no polycystic image at any of the ovaries, n=22), group 2 (with polycystic image at only one ovary, n=41), and group 3 (with polycystic image at both of the ovaries, n=22). Serum interleukin 6 (IL-6), hormone levels, and homeostasis model assessment-insulin resistance (HOMA-IR) were measured. Results: The mean serum IL-6 levels for groups 1, 2 and 3 were 14.65 ± 6.18 pg/mL, 16.22 ± 6.55 pg/mL, and 14:53 ± 7.32 pg/mL, respectively. There was no statically difference between three groups for serum IL-6 levels (p>0.05). For metabolic profile, the mean of HOMA-IR was 3.09±1.56 for group 2 and this was significantly lower than other groups (p

PDF

___

1. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81(1).19-25.
2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333(13):853-61.
3. Yildiz BO, Haznedaroğlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002;87(8):3871-5.
4. Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 2008;60(1):39-51.
5. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89(6):2583-9.
6. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21(6):1426-31.
7. Moscovitz H, Shofer F, Mignott H, Behrman A, Kilpatrick L. Plasma cytokine determinations in emergency department patients as a predictor of bacteremia and infectious disease severity. Crit Care Med 1994;22(7):1102-7.
8. Villuendas G, San Millán JL, Sancho J, Escobar-Morreale HF. The -597 G-->A and -174 G-->C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002;87(3):1134-41.
9. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271(5249):665-8.
10. Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically de fined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82(7):2248-56.
11. Legro RS, Chiu P, Kunselman AR, Bentley CM, Dodson WC, Dunaif A. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 2005;90(5):2571-9.
12. Birdsall MA, Farquhar CM. Polycystic ovaries in pre and post-menopausal women. Clin Endocrinol (Oxf) 1996;44(3):269-76.
13. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
14. Endl J, Otto H, Jung G, et al. Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest 1997;99(10):2405-15.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9.
16. Genuth S, Alberti KG, Bennett P, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26(11):3160-7.
17. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83(9):3078-82.
18. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Müller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90(11):6014- 21.
19. Dijsselbloem N, Vanden Berghe W, De Naeyer A, Haegeman G. Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anticancer and anti-inflammatory therapy. Biochem Pharmacol 2004;68(6):1171-85.
20. Rosenson RS, Tangney CC, Levine DM, Parker TS, Gordon BR. Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia. Atherosclerosis 2004;177(1):77- 81.
21. Frishman WH. Biologic markers as predictors of cardiovascular disease. Am J Med 1998;104(6A):18S- 27S.
22. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24(3):278-301.
23. Ranjit N, Diez-Roux AV, Shea S, et al. Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis. Arch Intern Med 2007;167(2):174-81.
24. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86(6):2453-5.
25. Kovacs GT. Polycystic ovarian disease: an overview. Rev Gynaecol Pract 2004;2(4):97-104.
26. Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000;73(1):150-6.
27. Fernández-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999;42(11):1367-74.
28. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148(2):209-14.